Shu, Y.; Shen, W.; Feng, W.; Pan, M.; Xu, X.; Zheng, S.; Jin, H.
Targeting HMGCS2: Ketogenesis Suppression Accelerates NAFLD Progression in T2DM Comorbidity, While Cynaroside Ameliorates NASH in Concomitant T2DM. Biomolecules 2025, 15, 1181.
https://doi.org/10.3390/biom15081181
AMA Style
Shu Y, Shen W, Feng W, Pan M, Xu X, Zheng S, Jin H.
Targeting HMGCS2: Ketogenesis Suppression Accelerates NAFLD Progression in T2DM Comorbidity, While Cynaroside Ameliorates NASH in Concomitant T2DM. Biomolecules. 2025; 15(8):1181.
https://doi.org/10.3390/biom15081181
Chicago/Turabian Style
Shu, Yongsheng, Wanqing Shen, Wanyu Feng, Meijun Pan, Xinyi Xu, Shuguo Zheng, and Huanhuan Jin.
2025. "Targeting HMGCS2: Ketogenesis Suppression Accelerates NAFLD Progression in T2DM Comorbidity, While Cynaroside Ameliorates NASH in Concomitant T2DM" Biomolecules 15, no. 8: 1181.
https://doi.org/10.3390/biom15081181
APA Style
Shu, Y., Shen, W., Feng, W., Pan, M., Xu, X., Zheng, S., & Jin, H.
(2025). Targeting HMGCS2: Ketogenesis Suppression Accelerates NAFLD Progression in T2DM Comorbidity, While Cynaroside Ameliorates NASH in Concomitant T2DM. Biomolecules, 15(8), 1181.
https://doi.org/10.3390/biom15081181